Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 9, 1996, Pages 2560-2568

  von Tempelhoff, G F ^a   Dietrich, M ^a   Hommel, G ^a   Heilmann, L ^a  

^a Gesundheits und Pflegezentrum Russelsheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; CYCLOPHOSPHAMIDE; EPIRUBICIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C;

ARTICLE; BLOOD CLOTTING; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMPEDANCE PLETHYSMOGRAPHY; INCIDENCE; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 0029738475     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.9.2560     Document Type: Article

References (48)

1. Booth BW, Weiss RB: Venous thrombosis during adjuvant chemotherapy. N Engl J Med 311:170, 1981 (letter)
2. Levine MN, Gent M, Hirsh J, et al: The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318:404-407, 1988
3. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286-294, 1991
4. Weiss RB, Tormey DC, Holland F, et al: Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 65:677-679, 1981
5. Goodnough LT, Saito H, Manni A, et al: Increased incidence of thromboembolism in stage IV breast cancer patients treated with five drug chemotherapy regimen. Cancer 54:1264-1268, 1984
6. Levine M, Hirsh J, Gent M, et al: Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolisrn in stage IV breast cancer. Lancet 343:886-889, 1994
7. Bick RL: Alterations of hemostasis associated with malignancy. Semin Thromb Hemost 5:1-26 1978
8. Komp DM, Lyles RL, Boyd TH, et al: The effect of cancer chemotherapeutic agents on fibrin formation and stabilization in vitro. Pediatr Res 8:75-81, 1974
9. Feffer SE, Carmasino LS, Fox RL: Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate and 5 fluorouracil. Cancer 63:1303-1307, 1989
10. Rogers JS, Murgo AJ, Fontana JA, et al: Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6:276-281, 1988
11. Doll DC, Ringenberg QS, Jarbro JW: Vascular toxicity associated with antineoplastic agents. Semin Oncol 19:580-596, 1992
12. Patterson WP, Ringenberg QS: The pathophysiology of thrombosis in cancer. Semin Oncol 17:140-146, 1990
13. Rickles FR, Levine M, Edwards RL, et al: Hemostatic alterations in cancer patients, in Serneri GGN, Gensini GF, Abbate R, et al (eds): Thrombosis: An Update. Scientific Press, 1992, pp 241-260
14. Rickles FR, Levine M, Edwards RL: Hemostatic alterations in cancer patients. Cancer Metast Rev 11:237-248, 1992
15. Bertomeu MC, Gallo S, Lauri D, et al: Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metast 8:511-518, 1990
16. Chahwala SB, Hickmann JA: Effect of the antitumor drug Adriamycin on human blood cell discocyte-echinocyte transitions. Cancer Res 45:4986-4989, 1985
17. Look MP, Musch E: Lipid peroxides in the polychemotherapy of cancer patients. Chemotherapy 40:8-15, 1994
18. Goldsmith HL, Turitto VT: Rheological aspect of thrombosis and hemostasis: Basic principles and applications. Thromb Hemost 55:415-435, 1986
19. Kaufmann M: Current and new concepts in the systemic adjuvant treatment of breast cancer. Onkologie 16:304-308, 1993
20. Wheeler HB, Anderson FA: Diagnostic methods for deep vein thrombosis. Haemostasis 25:6-26, 1995
21. Stief TW, Lenz P, Becker U, et al: Determinations of plasminogen activator inhibitor (PAI) capacity of human plasma in presence of oxidants, a novel principle. Thromb Res 50:559-573, 1988
22. Clagett GP, Reisch JS: Prevention of venous thromboembolism in general surgical patients. Ann Surg 208:227-240, 1988
23. Salzman EW, Hirsh J: Prevention of venous thromboembolism, in Colman RW, Hirsh J, Marder VJ, et al (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA, Lippincott, 1987, pp 1252-1265
24. Ludwig H: Klinisch-experimentelle Untersuchung zur thrombotischen Diathese bei der gynäkologischen Radiumbehandlung. Geburtshilfe Frauenheilkd 22:1121-1123, 1962
25. Canobbio L, Fassio T, Ardizzoni R, et al: Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 58:1032-1036, 1986
26. Clahsen PC, van der Velde CJH, Julien JP, et al: Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cooperative Group study. J Clin Oncol 12:1266-1271, 1994
27. Miller B, Heilmann L: Hemorheological parameters in patients with gynecologic malignancies. Gynecol Oncol 33:177-181, 1989
28. Naud S: Hemostatsis and cancer. Cancer J 6:54-58, 1993
29. Tempelhoff von G-F: Changes of hemorrheology and clotting in different gynecologic malignancies. Clin Hemorrheol 15:261-262, 1995
30. Rickles FR, Hancock WW, Edwards RI, et al: Antimetastatic agents, the role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and in the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemost 14:88-90, 1988
31. Zacharski LR: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon head neck and prostate. Cancer 53:2046-2053, 1984
32. Zacharski LR, Henderson WG, Rickles FR, et al: Rationale and experimental design for the VA cooperative study of anticoagulation (warfarin) in the treatment of cancer. Cancer 44:732-741, 1979
33. Dvorak HF, Dvorak AM, Manseau EJ, et al: Fibrin gel investment associated with line 1 and 10 solid tumor growth angiogenesis and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage and infarction in line 1 tumor regression. J Natl Cancer Inst 62:1459-1472, 1979
34. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al: Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 65:516-521, 1990
35. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al: Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 10:579-582, 1990
36. Costantini V, Zacharski LR: Fibrin and cancer. Thromb Hemost 69:406-414, 1993
37. Zacharski LR, Howell AL, Memoli VA: The coagulation biology of cancer. Fibrinolysis 6:39-42, 1992 (suppl)
38. Edwards RL, Klaus M, Mathews E, et al: Heparin abolishes the chemotherapy induced increase in plasma fibrinopeptide A levels. Am J Med 89:25-28, 1990
39. Seiffer EJ, Brooks BJ, Urba WJ: Possible interactions between warfarin and antineoplastic drugs. Cancer Treat Rep 69:244-245, 1985
40. de Jong E, Knot EAR, Iburg AHC, et al: Increased plasminogen activator inhibitor activator inhibition levels in malignancy. Thromb Hemost 57:140-143, 1987
41. Newland JR, Haire WD: Elevated plasminogen activator inhibitor levels found in patients with malignant conditions. Am J Clin Pathol 96:602-604, 1991
42. Rocha E, Paramo JA, Fernández FJ, et al: Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 54:699-707, 1989
43. Tempelhoff von G-F, Heilmann L: Hemostaseology and thrombosis in patients with nodal positive breast cancer. Ann Hematol 70:62, 1995 (suppl 1, abstr)
44. Semeraro N, Montemurro P, Conese M, et al: Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecologic malignancies. Int J Cancer 45:251-254, 1990
45. Falanga A, Ofuso FA, Delaini F, et al: The hypercoagulable state in cancer patients: Evidence for impaired thrombin inhibition. Blood Coagul Fibrinolysis 5:19-23, 1994 (suppl 1)
46. McCulloch P, Douglas J, Lowe GDO, et al: In vivo measurements of fibrin formation and fibrinolysis in operable breast cancer. Thromb Hemost 61:318-321, 1989
47. McCulloch P, Nieuwenhuizen W, Douglas J, et al: Coagulation disturbance in cancer of the breast and colon measured with specific monoclonal antibody enzyme immunoassay for fibrin-fibrinogen degradation products. Haemostasis 20:73-80, 1990
48. Lorenzent R, Oeri G, Locati D, et al: Generation of procoagulant activity by mononuclear phagocytes: A possible mechanism contributing to blood clotting activation within malignant tissues. Blood 62:271-273, 1983